Diphosphonates

"Diphosphonates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents.

Descriptor ID	D004164
MeSH Number(s)	D02.705.429.500
Concept/Terms	Diphosphonates Diphosphonates Bisphosphonates

Below are MeSH descriptors whose meaning is more general than "Diphosphonates".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Organophosphorus Compounds [D02.705]
Organophosphonates [D02.705.429]
Diphosphonates [D02.705.429.500]

Below are MeSH descriptors whose meaning is related to "Diphosphonates".

Below are MeSH descriptors whose meaning is more specific than "Diphosphonates".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Diphosphonates" by people in this website by year, and whether "Diphosphonates" was a major or minor topic of these publications.

Bar chart showing 44 publications over 21 distinct years, with a maximum of 6 publications in 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	1	0	1
2002	3	0	3
2003	3	0	3
2004	2	0	2
2005	2	0	2
2006	1	0	1
2008	1	0	1
2009	1	0	1
2010	1	0	1
2011	3	1	4
2012	3	0	3
2013	1	1	2
2014	4	2	6
2015	1	1	2
2016	2	1	3
2017	3	0	3
2018	1	1	2
2019	0	1	1
2020	0	1	1
2022	0	1	1
2024	0	1	1

Below are the most recent publications written about "Diphosphonates" by people in Profiles.

Hori Y, McDonald TC, Thornley P, Almeida da Silva LC, Kaymaz B, Rogers KJ, Yorgova PK, Bober MB, Carroll R, Kruse RW, Franzone JM, Shah SA. Midterm Outcomes of Multimodal Approach to Treating Severe Scoliosis in Patients With Osteogenesis Imperfecta. J Am Acad Orthop Surg. 2024 Sep 15; 32(18):e951-e960.

View in: PubMed
Xue L, Gong N, Shepherd SJ, Xiong X, Liao X, Han X, Zhao G, Song C, Huang X, Zhang H, Padilla MS, Qin J, Shi Y, Alameh MG, Pochan DJ, Wang K, Long F, Weissman D, Mitchell MJ. Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment. J Am Chem Soc. 2022 06 08; 144(22):9926-9937.

View in: PubMed
Sawamoto K, ?lvarez JV, Herre?o AM, Otero-Espinar FJ, Couce ML, Alm?ciga-D?az CJ, Tomatsu S. Bone-Specific Drug Delivery for Osteoporosis and Rare Skeletal Disorders. Curr Osteoporos Rep. 2020 10; 18(5):515-525.

View in: PubMed
Franzone JM, Shah SA, Wallace MJ, Kruse RW. Osteogenesis Imperfecta: A Pediatric Orthopedic Perspective. Orthop Clin North Am. 2019 Apr; 50(2):193-209.

View in: PubMed
Jain M, Tam A, Shapiro JR, Steiner RD, Smith PA, Bober MB, Hart T, Cuthbertson D, Krischer J, Mullins M, Bellur S, Byers PH, Pepin M, Durigova M, Glorieux FH, Rauch F, Lee B, Sutton VR, Nagamani SCS. Growth characteristics in individuals with osteogenesis imperfecta in North America: results from a multicenter study. Genet Med. 2019 02; 21(2):275-283.

View in: PubMed
Berglund JA, Tella SH, Tuthill KF, Kim L, Guthrie LC, Paul SM, Stanton R, Collins MT, Boyce AM. Scoliosis in Fibrous Dysplasia/McCune-Albright Syndrome: Factors Associated With Curve Progression and Effects of Bisphosphonates. J Bone Miner Res. 2018 09; 33(9):1641-1648.

View in: PubMed
Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, Novotny PJ, Borah BJ. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). J Clin Oncol. 2017 Dec 10; 35(35):3949-3955.

View in: PubMed
Yachoui R, Kreidy M, Parker BJ. Treatment-Refractory Sternocostoclavicular Hyperostosis. Clin Med Res. 2017 06; 15(1-2):37-40.

View in: PubMed
Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA. 2017 01 03; 317(1):48-58.

View in: PubMed
Lipton A, Smith MR, Fizazi K, Stopeck AT, Henry D, Brown JE, Shore ND, Saad F, Spencer A, Zhu L, Warner DJ. Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents. Clin Cancer Res. 2016 Dec 01; 22(23):5713-5721.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement